News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiva Medical, Inc. Announces U.S. Distribution for Hemostasis Products


7/27/2010 9:06:51 AM

SUNNYVALE, Calif., July 26 /PRNewswire/ -- Cardiva Medical, Inc. announced today that it has signed an agreement with Advanced Vascular Dynamics to distribute several products used for postcatheterization femoral and radial artery hemostasis in the U.S. These products include i) RadAR, an innovative radial artery compression device, ii) ComfortPress, an ergonomic hand-held manual compression assist device, iii) ExpressAR, an external mobile compression device and iv) Celox Vascular, a chitosan based hemostatic patch.

"We are delighted to offer these unique products to our customers in the US," said John McCurdy, Vice President of Sales. McCurdy continued, "The products complement our Catalyst femoral artery closure system and will enable our customers to take advantage of economical alternatives for femoral and radial artery closure." RadAR, ComfortPress, ExpressAR and Celox Vascular are used in cardiac catheterization labs, interventional radiology departments and intensive care units. "This helps us extend our product lines to more customers and enhance our level of onsite customer service. We are very pleased to work with Cardiva," said Matthew Semler, President of Advanced Vascular Dynamics.

About Cardiva Medical, Inc

Cardiva Medical, Inc. is a privately-held medical device company that designs, develops and commercializes endovascular products which help the body heal itself following percutaneous procedures. Annually, more than 10 million percutaneous procedures worldwide require closure. In 2005, Cardiva launched its first product into the vessel closure market, the Boomerang® Wire System, which demonstrated unsurpassed ease-of-use and safety. In January 2008, Cardiva launched the Cardiva Catalyst II, which incorporates hemostatic agents to accelerate the body's own coagulation pathway; quickly facilitating hemostasis at the arteriotomy site, preserving the artery and leaving absolutely nothing behind in the patient. In May 2009, Cardiva launched the Catalyst III system that is coated with protamine sulfate, a drug which neutralizes heparin in the tissue tract and facilitates quick and efficient vessel closure in patients undergoing anticoagulation with heparin. Cardiva is developing a next generation femoral artery closure system for diagnostic and interventional percutaneous procedures.

For additional information about Cardiva, please visit our website at www.cardivamedical.com.

Cardiva Catalyst, Boomerang and Boomerang Catalyst are trademarks/registered trademarks of Cardiva Medical, Inc.

Media Contact:

Malcolm Farnsworth

Chief Financial Officer

Cardiva Medical, Inc.

Phone: 480.470.7103

Mac_Farnsworth@cardivamedical.com



SOURCE Cardiva Medical, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES